Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Iron imbalance in cancer: Intersection of deficiency and overload.

Tytuł:
Iron imbalance in cancer: Intersection of deficiency and overload.
Autorzy:
Basak T; Institute for Innovation in Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia.
Kanwar RK; Institute for Innovation in Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia.; Department of Translational Medicine Centre, All India Institute of Medical Sciences (AIIMS) Bhopal, Bhopal, India.
Źródło:
Cancer medicine [Cancer Med] 2022 Oct; Vol. 11 (20), pp. 3837-3853. Date of Electronic Publication: 2022 Apr 22.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
MeSH Terms:
Trace Elements*
Iron Deficiencies*
Neoplasms*/complications
Humans ; Iron ; Reactive Oxygen Species ; Antioxidants ; Oxidative Stress ; Free Radicals ; Iron Chelating Agents ; Tumor Microenvironment
References:
Curr Sleep Med Rep. 2017 Mar;3(1):1-10. (PMID: 28944164)
Curr Atheroscler Rep. 2012 Dec;14(6):515-24. (PMID: 23001745)
Am J Clin Nutr. 2010 Dec;92(6):1406-15. (PMID: 20962160)
JCI Insight. 2020 Jan 30;5(2):. (PMID: 31996481)
Clin Nephrol. 2000 Jan;53(1):42-7. (PMID: 10661481)
Clin Biochem Rev. 2016 May;37(2):51-62. (PMID: 28303071)
Acta Med Okayama. 2020 Feb;74(1):1-6. (PMID: 32099242)
Int J Lab Hematol. 2012 Jun;34(3):274-82. (PMID: 22151199)
Cell. 2019 May 16;177(5):1262-1279.e25. (PMID: 31056284)
Heliyon. 2019 Jul 12;5(7):e02045. (PMID: 31338466)
Mol Aspects Med. 2020 Oct;75:100896. (PMID: 32912773)
PLoS One. 2013 Aug 14;8(8):e70955. (PMID: 23967140)
ACS Nano. 2019 Feb 26;13(2):2176-2189. (PMID: 30676731)
Cureus. 2020 Apr 9;12(4):e7607. (PMID: 32399341)
Ann Gastroenterol. 2017;30(4):405-413. (PMID: 28655976)
Nat Genet. 2005 Nov;37(11):1264-9. (PMID: 16227996)
BMC Med. 2014 Nov 26;12:229. (PMID: 25428714)
Blood. 2019 Jan 3;133(1):40-50. (PMID: 30401705)
N Engl J Med. 1992 Jan 9;326(2):95-100. (PMID: 1727237)
Oxid Med Cell Longev. 2015;2015:750798. (PMID: 26273424)
FEBS J. 2019 Mar;286(5):826-854. (PMID: 30028073)
Biochim Biophys Acta. 2010 Aug;1800(8):760-9. (PMID: 20304033)
Blood. 2011 Apr 28;117(17):4425-33. (PMID: 21346250)
Hematology. 2015 Jan;20(1):18-25. (PMID: 24666207)
Diabetes Spectr. 2014 Nov;27(4):276-80. (PMID: 25647050)
Biomolecules. 2018 Oct 25;8(4):. (PMID: 30366441)
Lancet. 2020 Jul 25;396(10246):277-287. (PMID: 32711803)
Oncotarget. 2017 Jun 16;8(44):77942-77956. (PMID: 29100437)
In Vivo. 2003 Sep-Oct;17(5):389-92. (PMID: 14598600)
Blood. 2018 Feb 22;131(8):899-910. (PMID: 29237594)
Annu Rev Nutr. 2018 Aug 21;38:97-125. (PMID: 30130469)
Free Radic Biol Med. 2015 Feb;79:337-42. (PMID: 24835768)
Blood Cells Mol Dis. 2004 Sep-Oct;33(2):120-4. (PMID: 15315789)
Drug Discov Today. 2016 Jan;21(1):143-149. (PMID: 26475962)
Cancers (Basel). 2019 Aug 20;11(8):. (PMID: 31434226)
Int J Hematol. 2018 Jan;107(1):7-15. (PMID: 29147843)
Lancet Haematol. 2020 Apr;7(4):e342-e350. (PMID: 32220343)
Nutrients. 2018 Dec 11;10(12):. (PMID: 30544934)
Int J Mol Sci. 2020 Mar 24;21(6):. (PMID: 32214052)
Clin Lab Med. 2015 Mar;35(1):73-91. (PMID: 25676373)
Kidney Int Suppl. 1999 Mar;69:S131-4. (PMID: 10084297)
Arch Intern Med. 2006 Nov 13;166(20):2253-9. (PMID: 17101944)
Clin Epidemiol. 2016 Apr 18;8:61-71. (PMID: 27186078)
Int J Chronic Dis. 2018 Mar 18;2018:9394060. (PMID: 29744352)
Front Physiol. 2019 Oct 09;10:1294. (PMID: 31649559)
Biomed Res. 2017;38(6):343-350. (PMID: 29225212)
Int J Mol Sci. 2020 Jan 22;21(3):. (PMID: 31979104)
Hematol Oncol Clin North Am. 2018 Apr;32(2):213-221. (PMID: 29458727)
Anaesthesist. 2020 Dec;69(12):919-925. (PMID: 33104871)
Ann Nutr Metab. 2001;45(3):91-101. (PMID: 11423700)
Nutrients. 2017 May 02;9(5):. (PMID: 28468320)
Mol Cancer Ther. 2013 Nov;12(11):2331-41. (PMID: 24030633)
Diabetes Care. 2020 Feb;43(2):265-271. (PMID: 31959642)
J Cell Mol Med. 2012 May;16(5):1085-93. (PMID: 21781276)
Gut. 1995 Nov;37(5):727-30. (PMID: 8549953)
Lancet. 2002 Mar 2;359(9308):786-90. (PMID: 11888608)
Eur J Cancer Prev. 1996 Feb;5(1):19-36. (PMID: 8664805)
Clin Chem. 2003 Jan;49(1):175-8. (PMID: 12507977)
J Hematol Oncol. 2018 May 10;11(1):64. (PMID: 29747682)
J Biol Chem. 2015 Apr 3;290(14):9101-10. (PMID: 25681445)
Int J Mol Sci. 2019 Jan 11;20(2):. (PMID: 30641920)
J R Soc Med. 1989 Dec;82(12):747-52. (PMID: 2693713)
Nutr J. 2010 Nov 02;9:50. (PMID: 21044319)
Cell. 2014 Jan 16;156(1-2):317-331. (PMID: 24439385)
Cancer Med. 2022 Oct;11(20):3837-3853. (PMID: 35460205)
Front Physiol. 2018 Sep 20;9:1294. (PMID: 30294279)
Oxid Med Cell Longev. 2017;2017:2597581. (PMID: 28770020)
Front Oncol. 2020 Apr 09;10:476. (PMID: 32328462)
Ann Fam Med. 2004 Mar-Apr;2(2):139-44. (PMID: 15083854)
Am J Hematol. 2006 Oct;81(10):760-7. (PMID: 16838333)
Antioxidants (Basel). 2019 Oct 21;8(10):. (PMID: 31640237)
Front Mol Biosci. 2019 Nov 22;6:116. (PMID: 31824960)
Sci Rep. 2019 Mar 18;9(1):4802. (PMID: 30886160)
BMC Cancer. 2013 Jun 24;13:307. (PMID: 23800380)
Breast Cancer Res Treat. 2015 May;151(1):191-8. (PMID: 25893586)
Am J Hum Genet. 1987 Aug;41(2):89-105. (PMID: 3475981)
Anticancer Res. 2016 Nov;36(11):6011-6020. (PMID: 27793928)
Pharmaceuticals (Basel). 2018 Sep 30;11(4):. (PMID: 30274354)
J Intern Med. 2020 Feb;287(2):153-170. (PMID: 31665543)
Int J Mol Sci. 2020 May 28;21(11):. (PMID: 32481481)
Hematology. 2010 Aug;15(4):236-9. (PMID: 20670483)
Oncol Rep. 2017 Dec;38(6):3693-3701. (PMID: 29039574)
Ann N Y Acad Sci. 2016 Mar;1368(1):149-61. (PMID: 26890363)
Transl Lung Cancer Res. 2020 Aug;9(4):1569-1584. (PMID: 32953528)
Compr Physiol. 2013 Jan;3(1):315-30. (PMID: 23720289)
Rev Bras Hematol Hemoter. 2016 Oct - Dec;38(4):325-330. (PMID: 27863761)
Pharmaceuticals (Basel). 2018 Aug 27;11(3):. (PMID: 30150598)
J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34. (PMID: 10511589)
Case Rep Hematol. 2017;2017:2494167. (PMID: 28133557)
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):12-31. (PMID: 24243555)
Oncologist. 2012;17(5):715-24. (PMID: 22531357)
Hum Mol Genet. 2007 Jun 1;16(11):1335-42. (PMID: 17412760)
Hypoxia (Auckl). 2015 Dec 11;3:83-92. (PMID: 27774485)
Int J Clin Exp Med. 2014 Jun 15;7(6):1542-53. (PMID: 25035778)
Sci Rep. 2015 May 13;5:10181. (PMID: 25970748)
Nutrients. 2015 Mar 31;7(4):2274-96. (PMID: 25835049)
Infect Immun. 2013 Oct;81(10):3503-14. (PMID: 23836822)
Br J Haematol. 2013 Jun;161(5):639-48. (PMID: 23573815)
Clin J Am Soc Nephrol. 2006 Sep;1 Suppl 1:S4-8. (PMID: 17699374)
EBioMedicine. 2019 Jan;39:461-471. (PMID: 30502056)
Free Radic Biol Med. 2011 Apr 1;50(7):841-7. (PMID: 21193031)
Case Rep Oncol. 2020 Jun 30;13(2):760-763. (PMID: 32774272)
Lab Invest. 2009 May;89(5):531-48. (PMID: 19308044)
Gastroenterology. 2011 Jul;141(1):292-9, 299.e1. (PMID: 21473866)
J Matern Fetal Neonatal Med. 2022 Feb;35(3):465-471. (PMID: 32079433)
Dis Markers. 2015;2015:818570. (PMID: 26543300)
BMC Cancer. 2019 Nov 21;19(1):1131. (PMID: 31752747)
Biomed Res Int. 2014;2014:761264. (PMID: 24587990)
Ann Gastroenterol. 2020 Jan-Feb;33(1):95-97. (PMID: 31892804)
EJIFCC. 2009 Aug 25;20(2):108-23. (PMID: 27683335)
Rev Bras Hematol Hemoter. 2012;34(6):459-63. (PMID: 23323072)
Carcinogenesis. 2009 Apr;30(4):645-54. (PMID: 19136476)
Biomed Pharmacother. 2016 Aug;82:44-8. (PMID: 27470337)
Blood. 2014 Jan 30;123(5):615-24. (PMID: 24297872)
Clin Chim Acta. 1996 Feb 28;245(2):139-200. (PMID: 8867884)
J Pregnancy. 2017;2017:4265091. (PMID: 29348938)
Adv Nutr. 2017 Jan 17;8(1):126-136. (PMID: 28096133)
Oncotarget. 2016 Mar 22;7(12):14002-14. (PMID: 26872376)
Blood Transfus. 2014 Jul;12(3):296-300. (PMID: 25074787)
Redox Rep. 2009;14(3):102-8. (PMID: 19490751)
Nutrients. 2017 Jun 28;9(7):. (PMID: 28657578)
Mol Cell Biochem. 2011 Nov;357(1-2):171-9. (PMID: 21625956)
Mol Cancer. 2016 Feb 24;15:18. (PMID: 26905733)
Saudi J Biol Sci. 2021 Jan;28(1):50-54. (PMID: 33424282)
Am J Clin Nutr. 2017 Dec;106(Suppl 6):1634S-1639S. (PMID: 29070560)
Br J Haematol. 1990 Apr;74(4):525-30. (PMID: 2346731)
J Biol Chem. 2010 Dec 10;285(50):38832-40. (PMID: 20923773)
J Trace Elem Med Biol. 2020 Dec;62:126582. (PMID: 32673942)
Ann Oncol. 2013 Jul;24(7):1886-1892. (PMID: 23567147)
Front Cell Dev Biol. 2019 Jan 29;7:4. (PMID: 30761299)
N Engl J Med. 1988 May 26;318(21):1355-62. (PMID: 3367936)
Haematologica. 2015 Jan;100(1):124-32. (PMID: 25239265)
Free Radic Biol Med. 2017 Mar;104:144-164. (PMID: 28088622)
Front Pharmacol. 2018 Jan 12;8:992. (PMID: 29375387)
Wien Klin Wochenschr. 2015 Dec;127(23-24):907-19. (PMID: 26373748)
Oxid Med Cell Longev. 2016;2016:8629024. (PMID: 27006749)
Contributed Indexing:
Keywords: anaemia; cancer; inflammation; iron; iron deficiency; iron overload; reactive oxygen species (ROS)
Substance Nomenclature:
E1UOL152H7 (Iron)
0 (Reactive Oxygen Species)
0 (Antioxidants)
0 (Trace Elements)
0 (Free Radicals)
0 (Iron Chelating Agents)
Entry Date(s):
Date Created: 20220423 Date Completed: 20221021 Latest Revision: 20221104
Update Code:
20240105
PubMed Central ID:
PMC9582687
DOI:
10.1002/cam4.4761
PMID:
35460205
Czasopismo naukowe
Iron, an essential trace element, plays a complex role in tumour biology. While iron causes cancer clearance through toxic free radical generation, iron-induced free radical flux also acts as a cancer promoter. These fates majorly guided through cellular response towards pro-oxidant and antioxidant settings in a tumour microenvironment, designate iron-induced oxidative stress as a common yet paradoxical factor in pro-tumorigenesis as well as anti-tumorigenesis, posing a challenge to laying down iron thresholds favouring tumour clearance. Additionally, complexity of iron's association with carcinogenesis has been extended to iron-induced ROS's involvement in states of both iron deficiency and overload, conditions identified as comparable, inevitable and significant coexisting contributors as well as outcomes in chronic infections and tumorigenesis. Besides, iron overload may also develop as an unwanted outcome in certain cancer patients, as a result of symptomatic anaemia treatment owed to irrational iron-restoration therapies without a prior knowledge of body's iron status with both conditions synergistically acting towards tumour aggravation. The co-play of iron deficiency and overload along with iron's pro-tumour and antitumour roles with intersecting mechanisms, thus presents an unpredictable regulatory response loop in a state of malignancy. The relevance of iron's thresholds beyond which it proves to be beneficial against tumorigenesis hence becomes questionable. These factors pose a challenge, over establishing if iron chelation or iron flooding acts as a better approach towards antitumour therapies. This review presents a critical picture of multiple contrasting features of iron's behaviour in cancer, leading towards two conditions lying at opposite ends of a spectrum: iron deficiency and overload in chronic disease conditions including cancer, hence, validating the critical significance of diagnosis of patients' iron status prior to opting for subsequent therapies.
(© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies